Aestus receives $244.

Announced that it’s been awarded a $244,000 grant from the U.S. Government’s Qualifying Therapeutic Discovery Task plan. The grant, awarded for the project, ‘Treating neuropathic discomfort by way of novel mechanisms,’ will fund medical trials of Aestus’s novel, first-in-class treatment for persistent neuropathic pain. PHN is defined as persistent pain following an outbreak of herpes zoster commonly, or shingles. Based on the National Institutes of Health , several million new cases of shingles are reported each full yr in the United States, many of that may lead to PHN. Currently there is absolutely no effective treatment to alleviate the lingering discomfort of PHN which can be poorly managed by current medications.This critically important program is expected to result in a model for creating a unique, rather than one-size fits all, robotic prosthetic device for an amputee, lower costs for embedding sensors within a limb, and an advanced integrated control system which allows for lighter, more comfortable and even more cost-effective prostheses, stated Back Admiral Richard Brooks, USN , Alion’s Distributed Simulation Group Manager. Our modeling and simulation knowledge will greatly help facilitate developments in neuro-scientific artificial limbs. Alion is certainly partnering with Sigenics Inc. Of Chicago, IL on the agreement.